×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
IDYA – ideaya biosciences, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
IDYA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/9
06:22 am
idya
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update [Yahoo! Finance]
Medium
Report
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update [Yahoo! Finance]
3/9
06:00 am
idya
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update
Low
Report
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update
3/6
10:36 am
idya
IDEAYA Biosciences, Inc. (IDYA) Enrolls First Patient in Phase 1 Trial of IDE034 Bispecific ADC [Yahoo! Finance]
Low
Report
IDEAYA Biosciences, Inc. (IDYA) Enrolls First Patient in Phase 1 Trial of IDE034 Bispecific ADC [Yahoo! Finance]
2/27
07:19 pm
idya
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA's First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034 [Yahoo! Finance]
Low
Report
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA's First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034 [Yahoo! Finance]
2/27
07:00 pm
idya
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034
Low
Report
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034
2/27
07:00 pm
idya
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034
Low
Report
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034
2/27
06:00 am
idya
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2/25
06:00 am
idya
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC
Low
Report
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/2
07:18 pm
idya
Form 4 IDEAYA Biosciences, Inc. For: Mar 02 Filed by: Stein Jeffrey
Low
Report
Form 4 IDEAYA Biosciences, Inc. For: Mar 02 Filed by: Stein Jeffrey
2/17
04:56 pm
idya
Form S-8 IDEAYA Biosciences, Inc.
Low
Report
Form S-8 IDEAYA Biosciences, Inc.
2/17
04:29 pm
idya
Form SCHEDULE 13G/A IDEAYA Biosciences, Inc. Filed by: Point72 Asset Management, L.P.
Low
Report
Form SCHEDULE 13G/A IDEAYA Biosciences, Inc. Filed by: Point72 Asset Management, L.P.
2/17
04:02 pm
idya
Form 10-K IDEAYA Biosciences, Inc. For: Dec 31
Low
Report
Form 10-K IDEAYA Biosciences, Inc. For: Dec 31
2/17
06:10 am
idya
Form 8-K IDEAYA Biosciences, Inc. For: Feb 17
Low
Report
Form 8-K IDEAYA Biosciences, Inc. For: Feb 17
2/12
10:26 am
idya
Form SCHEDULE 13G/A IDEAYA Biosciences, Inc. Filed by: Capital Research Global Investors
Low
Report
Form SCHEDULE 13G/A IDEAYA Biosciences, Inc. Filed by: Capital Research Global Investors
2/2
08:05 pm
idya
Form 4 IDEAYA Biosciences, Inc. For: Jan 30 Filed by: Bleharski Joshua
Low
Report
Form 4 IDEAYA Biosciences, Inc. For: Jan 30 Filed by: Bleharski Joshua
2/2
08:04 pm
idya
Form 4 IDEAYA Biosciences, Inc. For: Jan 30 Filed by: WHITE MICHAEL ANTHONY
Low
Report
Form 4 IDEAYA Biosciences, Inc. For: Jan 30 Filed by: WHITE MICHAEL ANTHONY
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
11/13
Q3/2019 9/30/2019 EPS -0.540 ZacksConsensus -0.670 ActVsEst 0.130 - Beat
47.4%
12/18 Form 8-K IDEAYA Biosciences, Inc. For: Dec 17 14.3%
3/24 Q4/2019 12/31/2019 EPS -0.530 ZacksConsensus -0.570 ActVsEst 0.040 - Beat 12.0%
12/19 Form 3 IDEAYA Biosciences, Inc. For: Dec 17 Filed by: YARNO WENDY L 11.8%
4/7 Form 8-K IDEAYA Biosciences, Inc. For: Apr 06 10.9%
9/9 IDEAYA Biosciences (NASDAQ: IDYA) is now covered by analysts at Robert W. Baird. They set an "outperform" rating on the stock. 9.9%
11/19 IDEAYA Biosciences (NASDAQ: IDYA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $8.75 price target on the stock. 8.9%
4/6 IDEAYA Biosciences (NASDAQ: IDYA) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock. 8.5%
10/31 IDEAYA Biosciences Reports End-of-Phase 1 Meeting with FDA for IDE196 Confirms Acceptability of Single-Arm Trial Design for Potential Phase 2 Registration-Enabling Study in Metastatic Uveal Melanoma 7.9%
1/10 IDEAYA Biosciences and Boston Children's Hospital Collaborate on Preclinical Evaluation of IDE196 for Sturge Weber Syndrome - a Rare Disease Associated with Genetic Mutation of GNAQ 7.5%
12/18 Form 8-K IDEAYA Biosciences, Inc. For: Dec 17 14.3%
3/24 Q4/2019 12/31/2019 EPS -0.530 ZacksConsensus -0.570 ActVsEst 0.040 - Beat 12.0%
12/19 Form 3 IDEAYA Biosciences, Inc. For: Dec 17 Filed by: YARNO WENDY L 11.8%
4/7 Form 8-K IDEAYA Biosciences, Inc. For: Apr 06 10.9%
9/9 IDEAYA Biosciences (NASDAQ: IDYA) is now covered by analysts at Robert W. Baird. They set an "outperform" rating on the stock. 9.9%
11/19 IDEAYA Biosciences (NASDAQ: IDYA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $8.75 price target on the stock. 8.9%
4/6 IDEAYA Biosciences (NASDAQ: IDYA) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock. 8.5%
10/31 IDEAYA Biosciences Reports End-of-Phase 1 Meeting with FDA for IDE196 Confirms Acceptability of Single-Arm Trial Design for Potential Phase 2 Registration-Enabling Study in Metastatic Uveal Melanoma 7.9%
1/10 IDEAYA Biosciences and Boston Children's Hospital Collaborate on Preclinical Evaluation of IDE196 for Sturge Weber Syndrome - a Rare Disease Associated with Genetic Mutation of GNAQ 7.5%
TOP News Decliners
11/20
Phase 1/2 Clinical Trial Data for IDE196 Presented at Society for Melanoma Research Congress
-23.8%
3/11 IDEAYA Biosciences and Cancer Research UK Announce Expanded Research Collaboration for PARG, a DDR-Based Synthetic Lethality Target, Evaluating DNA Replication Vulnerabilities -20.3%
5/22 Form CERT IDEAYA Biosciences, Inc. -20.1%
8/1 Form 4 IDEAYA Biosciences, Inc. For: Jul 30 Filed by: Hata Yujiro S -11.6%
10/17 IDEAYA Biosciences (NASDAQ: IDYA) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $17.00 price target on the stock. -10.7%
1/16 IDEAYA Biosciences (NASDAQ: IDYA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -9.5%
4/1 IDEAYA Biosciences (NASDAQ: IDYA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -9.0%
1/29 IDEAYA Biosciences (NASDAQ: IDYA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $9.75 price target on the stock. -6.1%
2/6 Form SC 13G IDEAYA Biosciences, Inc. Filed by: CANAAN X L.P. -4.9%
11/13 Form 8-K IDEAYA Biosciences, Inc. For: Nov 13 -4.7%
3/11 IDEAYA Biosciences and Cancer Research UK Announce Expanded Research Collaboration for PARG, a DDR-Based Synthetic Lethality Target, Evaluating DNA Replication Vulnerabilities -20.3%
5/22 Form CERT IDEAYA Biosciences, Inc. -20.1%
8/1 Form 4 IDEAYA Biosciences, Inc. For: Jul 30 Filed by: Hata Yujiro S -11.6%
10/17 IDEAYA Biosciences (NASDAQ: IDYA) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $17.00 price target on the stock. -10.7%
1/16 IDEAYA Biosciences (NASDAQ: IDYA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -9.5%
4/1 IDEAYA Biosciences (NASDAQ: IDYA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -9.0%
1/29 IDEAYA Biosciences (NASDAQ: IDYA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $9.75 price target on the stock. -6.1%
2/6 Form SC 13G IDEAYA Biosciences, Inc. Filed by: CANAAN X L.P. -4.9%
11/13 Form 8-K IDEAYA Biosciences, Inc. For: Nov 13 -4.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: